The Exploratory Study on the Nicotinamide Mononucleotide (Vital NAD ) to Promote the Rejuvenation of the Peripheral Blood Immune Cells of Adults.
NCT ID: NCT05984550
Last Updated: 2023-08-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
EARLY_PHASE1
10 participants
INTERVENTIONAL
2023-08-31
2024-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
NAD+ Supplement（NMN）With Radioimmunotherapy in Advanced NSCLC
NCT06966583
Clinical Study of Multiple Dose Genakumab for Injection in Chinese Healthy Adults
NCT05894148
CCRT Followed by PD-1 Inhibitor Maintenance Therapy in Locally Advanced ESCC
NCT06964568
Phase I Clinical Trial of 68Ga-NOTA-SNA002
NCT05989997
Anti-PD-1 Immunotherapy Combined With SBRT for Patients With Oligometastatic ESCC
NCT05626569
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
treated group
NMN(Vital NAD) treated group
NMN
NMN (Nicotinamide Mononucleotide) is a naturally occurring bioactive nucleotide with the full name of Nicotinamide mononucleotide. Its structure can be divided into α and β Two isomers, of which only β- NMN is a naturally occurring form with biological activity.
In human body, NMN is the precursor of NAD+(Nicotinamide adenine dinucleotide, also known as coenzyme I), and its function is mainly reflected through NAD+.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
NMN
NMN (Nicotinamide Mononucleotide) is a naturally occurring bioactive nucleotide with the full name of Nicotinamide mononucleotide. Its structure can be divided into α and β Two isomers, of which only β- NMN is a naturally occurring form with biological activity.
In human body, NMN is the precursor of NAD+(Nicotinamide adenine dinucleotide, also known as coenzyme I), and its function is mainly reflected through NAD+.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Able to provide written Informed Consent.
3. BMI 25.0-44.9 kg/m².
4. Able to follow verbal and written study directions.
5. Must not be taking or be willing to take any supplements containing any form of niacin for seven days prior to baseline and for the duration of the study.
6. Able to maintain consistent diet and lifestyle habits according to the study.
Exclusion Criteria
2.Premenopausal or menopause \<1 year.
3.Persons who have received hormone replacement therapy within the past 6 months.
4.Persons who take vitamin B supplementation and are not willing to discontinue supplementation for 3 weeks before and during the entire study period.
5.Unstable weight (\>3% change during the last 2 months before entering the study).
6.Significant organ system dysfunction or disease.
7.Present cancer or history of cancer that has been in remission for \<5 years.
8.Polycystic ovary syndrome.
9.Major psychiatric illness.
10.Use of medications known to affect study outcome measures (e.g., steroid) or increase the risk of study procedures (e.g., anticoagulants) that cannot be temporarily discontinued for the study.
11.Metal implants.
12.Persons who consume \>14 units of alcohol per week.
13.Unable or unwilling to follow the study protocol or who, for any reason, is considered an inappropriate candidate for the study by the research team.
18 Years
80 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shanghai Mengchao Cancer Hospital
OTHER
Shanghai Cell Therapy Group Co.,Ltd
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Shanghai Mengchao Cancer Hospital
Shanghai, , China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Zongchang Song
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CH2301-A-02
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.